Travere reports Q2 loss, FILSPARI launch progress, and $445M bile acid portfolio sale

Travere Therapeutics, Inc.

2023-Q2 EPS reported -$2.38 revenue$116,690,000

Net loss $85.6M ($1.13/share) vs $67M loss in prior year; revenue $59.7M from product sales $57M and licensing.
FILSPARI launch: 417 new patient start forms in Q2; net sales $3.5M in Q2, $6.5M since Feb approval.
Positive pegtibatinase Cohort 6 results: 67.1% mean tHcy reduction; Phase 3 study expected by year-end.
Agreement to sell bile acid portfolio (Cholbam, Chenodal) to Mirum for up to $445M ($210M upfront); close Q3 2023.
Cash $491.3M; topline confirmatory PROTECT data for IgAN sNDA expected late Q3/early Q4.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Travere Therapeutics, Inc. reported the second quarter of 2023 results: revenue $59.7 million, net income $1.13 per basic share, EPS $1.13 per basic share.

Period: the second quarter of 2023
Revenue: $59.7 million
Net income: $1.13 per basic share
EPS: $1.13 per basic share
Result: reported results

Exact text from the filing

treatment standards from pipeline and strengthens financial foundation; transaction expected to close in third quarter of 2023 • Total revenue for the second quarter of 2023 was $59.7 million, consisting of $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of June 30,

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.